Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Uterine Cervical Neoplasms 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphatic Metastasis 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Adenosquamous 1Adenocarcinoma 1

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × fluoroazomycin arabinoside × Clear all
NCT04409314 2023-08-21

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

University of California, San Francisco

Completed
23 enrolled
LymphoidPlasma cell

Multiple Myeloma, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡